Aimovig

Erenumab (trade name Aimovig) is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It was the first of the group of CGRPR antagonists to be approved in 2018.

Uses

• Erenumab is approved for prevention of migraine in adults.
• It is administered by subcutaneous injection of 70 or 140 mg once a month.

Pharmacology

• Erenumab is a fully human monoclonal antibody of calcitonin gene-related peptide receptor (CGRPR).